GW Pharmaceuticals News Releases http://ir.gwpharm.com/ GW Pharmaceuticals News Releases en GW Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, 2019 http://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-present-bank-america-merrill-lynch-healthcare LONDON, May 09, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Thu, 09 May 2019 08:35:39 -0400 GW Pharmaceuticals News Releases 10766 GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2019 http://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-plc-reports-financial-results-and-0 - Epidiolex U.S. Q1 net sales of $33.5m - - Positive Phase 3 pivotal results in Tuberous Sclerosis Complex, sNDA submission expected in Q4 2019 - - Conference call today at 4:30 p.m. EDT - CARLSBAD, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or Mon, 06 May 2019 16:01:14 -0400 GW Pharmaceuticals News Releases 10736 GW Pharmaceuticals Reports Positive Phase 3 Pivotal Trial Results for EPIDIOLEX® (cannabidiol) Oral Solution in Patients with Seizures Associated With Tuberous Sclerosis Complex http://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-reports-positive-phase-3-pivotal-trial - Achieved primary efficacy measure with both EPIDIOLEX doses as compared to placebo - - Represents the fifth consecutive positive Phase 3 pivotal trial for EPIDIOLEX - - Expect to file sNDA in Q4 2019 -  CARLSBAD, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. Mon, 06 May 2019 16:01:12 -0400 GW Pharmaceuticals News Releases 10741 GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on Epidiolex® (cannabidiol) oral solution, CV at the 2019 American Academy of Neurology Annual Meeting http://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-and-us-subsidiary-greenwich-biosciences-4 Meeting activities include presentations of Phase 3 data, cannabinoid education for clinicians, and a virtual reality experience CARLSBAD, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), the world leader in the development and Thu, 02 May 2019 07:00:31 -0400 GW Pharmaceuticals News Releases 10721 GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Period Ending March 31, 2019 and Host Conference Call on May 6, 2019 http://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-plc-report-financial-results-and-0 LONDON, April 23, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on May 6, 2019 its Tue, 23 Apr 2019 13:40:16 -0400 GW Pharmaceuticals News Releases 10676 GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Appointment of Darren Cline as U.S. Chief Commercial Officer http://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-and-its-us-subsidiary-greenwich-biosciences-7 CARLSBAD, Calif., April 11, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, today announced the appointment of Darren Cline as its new U.S. Thu, 11 Apr 2019 16:05:15 -0400 GW Pharmaceuticals News Releases 10641 GW Pharmaceuticals plc Announces the Sale of Priority Review Voucher for $105M http://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-plc-announces-sale-priority-review-voucher CARLSBAD, Calif. , March 18, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, today announced that GW Research Ltd. Mon, 18 Mar 2019 07:30:00 -0400 GW Pharmaceuticals News Releases 10621 GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Quarter Ended December 31, 2018 http://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-plc-reports-financial-results-and-operational – Epidiolex ® (cannabidiol) oral solution (CV), first FDA-approved plant-derived cannabinoid medicine, launched in the U.S. in November to high awareness and demand – – GW moves to a new fiscal year-end beginning January 1, 2019 – – Conference call today at 4:30 p.m. Tue, 26 Feb 2019 16:01:09 -0500 GW Pharmaceuticals News Releases 10481 GW Pharmaceuticals to Present at Upcoming Investor Conferences http://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-present-upcoming-investor-conferences-4 - Leerink Partners 8 th Annual Global Healthcare Conference on February 28, 2019 - - Cowen and Company 39 th Annual Health Care Conference on March 11, 2019 - LONDON and CARLSBAD, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the Tue, 26 Feb 2019 11:08:20 -0500 GW Pharmaceuticals News Releases 10471 GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Period Ending 31 December 2018 and Host Conference Call on 26 February 2019 http://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-plc-report-financial-results-and-operational LONDON, Feb. 07, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 26 February, 2019 its Thu, 07 Feb 2019 15:21:49 -0500 GW Pharmaceuticals News Releases 10426